The mystery of chromosomal translocations in cancer.
Chromosomal translocations in human cancer may result in products that can be suppressed by targeting drugs. An example is bcr-abl tyrosine kinase in chronic myelogenous leukemia that can be treated with imatinib mesylate. However, the mechanisms of translocations or exchanges of chromosomal segments are virtually unknown. In this summary, chromosomal translocations in human cancer are compared with 'crossing over' of chromosomal segments occurring during the first meiotic division. Several proposed mechanisms of the exchange of DNA between and among chromosomes are discussed. The conditions that appear essential for these events to occur are listed. Among them are proximity of the involved DNA segments, mechanisms of excising the target DNA, its transport to the new location, and integration into the pre-existing chromosome. The conclusion based on extensive review of the literature is that practically nothing is known about the mechanism of 'crossing over' or translocation. Based on prior work on normal human cells, it is suggested that only one of the two autosomes participates in these events that may include loss of heterozygozity, another common abnormality in human cancer.
Koss
L G
LG
Department of Pathology, Montefiore Medical Center, Bronx, NY, USA. lkoss@montefiore.org
D003434:Crossing Over, Genetic; D006801:Humans; D019656:Loss of Heterozygosity; D008540:Meiosis / Q000235:genetics; D009369:Neoplasms / Q000235:genetics*; D014178:Translocation, Genetic